Back to Search
Start Over
Precise In Situ Delivery of a Photo-Enhanceable Inflammasome-Activating Nanovaccine Activates Anticancer Immunity.
- Source :
-
Cancer research [Cancer Res] 2024 Nov 15; Vol. 84 (22), pp. 3834-3847. - Publication Year :
- 2024
-
Abstract
- A variety of state-of-the-art nanovaccines (NV) combined with immunotherapies have recently been developed to treat malignant tumors, showing promising results. However, immunosuppression in the tumor microenvironment (TME) restrains cytotoxic T-cell infiltration and limits the efficacy of immunotherapies in solid tumors. Therefore, tactics for enhancing antigen cross-presentation and reshaping the TME need to be explored to enhance the activity of NVs. Here, we developed photo-enhanceable inflammasome-activating NVs (PIN) to achieve precise in situ delivery of a tumor antigen and a hydrophobic small molecule activating the nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome (NLRP3) pathway. Near-infrared light irradiation promoted PIN accumulation in tumor sites through photo-triggered charge reversal of the nanocarrier. Systematic PIN administration facilitated intratumoral NLRP3 inflammasome activation and antigen cross-presentation in antigen-presenting cells upon light irradiation at tumor sites. Furthermore, PIN treatment triggered immune responses by promoting the production of proinflammatory cytokines and activating antitumor immunity without significant systematic toxicity. Importantly, the PIN enhanced the efficacy of immune checkpoint blockade and supported the establishment of long-term immune memory in mouse models of melanoma and hepatocellular carcinoma. Collectively, this study reports a safe and efficient photoresponsive system for codelivery of antigens and immune modulators into tumor tissues, with promising therapeutic potential. Significance: The development of a photoresponsive nanovaccine with spatiotemporal controllability enables robust tumor microenvironment modulation and enhances the efficacy of immune checkpoint blockade, providing an effective immunotherapeutic strategy for cancer treatment. See related commentary by Zhen and Chen, p. 3709.<br /> (©2024 The Authors; Published by the American Association for Cancer Research.)
- Subjects :
- Animals
Mice
Humans
Mice, Inbred C57BL
Immunotherapy methods
Female
Cell Line, Tumor
Melanoma, Experimental immunology
Melanoma, Experimental therapy
Melanoma, Experimental drug therapy
Melanoma, Experimental pathology
Antigens, Neoplasm immunology
Nanovaccines
Inflammasomes immunology
Tumor Microenvironment drug effects
Tumor Microenvironment immunology
NLR Family, Pyrin Domain-Containing 3 Protein immunology
NLR Family, Pyrin Domain-Containing 3 Protein metabolism
Cancer Vaccines immunology
Cancer Vaccines administration & dosage
Nanoparticles chemistry
Nanoparticles administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1538-7445
- Volume :
- 84
- Issue :
- 22
- Database :
- MEDLINE
- Journal :
- Cancer research
- Publication Type :
- Academic Journal
- Accession number :
- 39288074
- Full Text :
- https://doi.org/10.1158/0008-5472.CAN-24-0220